Xtrava’s Spera COVID-19 Test Gets FDA’s Emergency Use Authorization

Santa Clara, Calif.-based Xtrava Health has received the FDA’s Emergency Use Authorization (EUA) for its COVID-19 antigen test, dubbed the Spera COVID-19 Ag Test.

The test uses immunochromatographic technology to detect SARS-CoV-2 nucleocapsid protein in anterior nasal swab specimens.

The EUA covers the qualitative detection of nucleocapsid protein antigen from the SARS-CoV-2 virus in direct anterior nasal swabs from individuals suspected of COVID-19 by their healthcare provider within the first five days of symptoms.